Abbvie ((ABBV)), Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
AbbVie is currently conducting a Phase 2 clinical study titled A Phase 2, Open-Label, Randomized Study of Livmoniplimab in Combination With Budigalimab Versus Chemotherapy in Subjects With Metastatic Urothelial Carcinoma. The study aims to evaluate the safety and efficacy of livmoniplimab combined with budigalimab compared to standard chemotherapy in treating metastatic urothelial carcinoma, a cancer with significant unmet treatment needs.
The study tests two investigational drugs, livmoniplimab and budigalimab, both administered intravenously. These drugs are intended to provide a new treatment option for patients with metastatic urothelial carcinoma.
This interventional study is randomized and follows a parallel assignment model with no masking. Its primary purpose is treatment, focusing on assessing the safety and effectiveness of the drug combination.
The study began on January 20, 2025, with an estimated completion timeline of approximately 3.5 years. The latest update was submitted on June 24, 2025, indicating the study is actively recruiting participants.
For investors, this study could influence AbbVie’s stock performance by potentially expanding its oncology portfolio if successful. The study’s progress and outcomes may also affect investor sentiment, especially in comparison to competitors in the oncology sector.
The study is ongoing, with further details available on the ClinicalTrials portal.